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Abstract  
 
The information disclosed by the companies in their annual reports reveals much about 
company’s performance and prospects. Investors take the information as base for decision 
for investment. Under such circumstance, companies choose to disclose beyond what is 
mandatorily required. Theories like agency theory, capital need theory and signaling theory 
support the need of voluntary disclosure. This study is about investigating the extent of 
Voluntary disclosure in pharmaceutical sector of India which is 3rd in World in terms of 
Volume of Trade.  
Objective: To investigate the extent of voluntary disclosure practices prevailing in pharma 
sector of India, for the year 2010-11 to 2017-18. 
Significance of the study: This study aims to explore the corporate aspect of 
pharmaceutical sector. Any growing avenue is a potential opportunity for investors looking 
for parking their money to get adequate returns. Thus, Indian Pharma sector has come up 
in flying colors as an avenue for investors to place their money owing to its 100% FDI. 
Investors have been looking for more and more information from this sector to ensure the 
safety of funds. Thus, the extent of disclosures is worth studying to place a suggestion for 
the policymakers to introduce the changes in the present set of disclosure practices in 
pharmaceutical sector.  
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Research Methodology: To understand the extent of voluntary disclosure, a disclosure 
checklist is constructed and descriptive statistics are carved out to reach the results. The 
checklist consists of 55 items which are not mandatory by law. The checklist is based on 
dichotomous scale of ‘1’ and ‘0’ representing presence and absence of the checklist item 
respectively. The cross-sectional analysis is carried out to investigate the year wise and 
company wise disclosure for eight years.  
Findings: Though the study observes an increasing trend in the disclosure scores, but the 
findings are alarming to state that the highest score attained by any company throughout 
the period of 8 years was 37 (out of 55) not even meeting 80% of the total checklist score. 
This shows that pharmaceutical sector is not so friendly at disclosures. The probable 
reasons for such startling results are discussed in the study.  
 
1. Introduction  
 
Indian pharmaceutical industry has not only shown remarkable performance in the country 
but also established its foothold in overseas market. It is playing a vital role in promoting 
and sustaining development in the field of medicines and boasts of quality products in 
which are also approved by regulatory authorities of UK and USA. According to FICCI 
Report (2013) the pharmaceutical products have been catering to more than 95% 
pharmaceutical needs of the country with a population of 130crore. It has progressed 
significantly by shifting from traditional business practices to exploring and adapting new 
business strategies. Indian pharma companies have come up with desired competencies not 
only in their manufacturing abilities but in the processing of marketing and getting huge 
product acceptance abroad too. International brands associated with Indian pharma 
industries have been a significant platform for pharma companies to channelize their 
capabilities and convert them into opportunities to expand themselves to mark a presence 
on the global map.  
Indian pharmaceutical sector has been making a spectacular growth especially since last 
decade. In terms of volume of business, it is placed on 3rd place and in terms of value it is 
at 13th position worldwide, making it one of the prominent sectors of manufacturing in the 
country. India owes such remarkable growth of pharmaceuticals to foreign direct 
investment which is 100% in green field and 75% in brown field. A highly organized sector 
of Indian economy, pharmaceutical industry is growing at 8-9% annually. Ranging from 
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simple headache pills to complex Heart compounds, almost every type of medicine in made 
in India now.  
There has been a paradigm shift in the policies and regulations governing Indian 
pharmaceutical industry that made, from being almost non-existent in 1970s transformed 
to a 6-Billion USD market in World. Drug Control Authority has done away with Industrial 
licensing for most of the drugs. Innovative scientific manpower, affordable research and 
development costs and equipped laboratories have given a new face to Indian 
Pharmaceutical industry which is self-reliant and technologically strong. Also, the role of 
Intellect Property protection rights is adding to the strength of pharma industry. Any 
company or individual can patent the formula which gives relief from imitation and 
malpractices of trade.  
Indian pharmaceutical industry could be among pioneers to bring biogeneric i.e. generic 
versions of biological product in the organized form to the market. Today it is world’s 
largest source of generic drugs, supplying almost 40 percent of total drug requirement of 
the US and a quarter of generic medicine demand of the UK (source: www.pharmaceutical-
technology.com). 
The industry is highly fragmented with more than 20,000 registered units which are 
fragmented all over the country. The industry is connected to length and breadth of the 
country connecting Kolkata in east to Mumbai and Pune in West extending to Bengluru in 
South and Himachal Pradesh (Baddi is emerging as pharmaceutical capital of India) in 
North. Country’s large and diverse characteristic makes it a prime location for clinical 
trials. The industry is gradually discovering its niche of pharmaceutical formulations. Apart 
from that, bulk drugs and drug intermediaries are gaining momentum in the industry too. 
 
Over the last 35 years of its existence and growth, Indian pharmaceutical market has shown 
its strong longevity. The significance of pharma industry can be gauged from the various 
parameters of its development and contributions that it makes to the country (as discussed 
in section 2.2 of the thesis)  
Fierce policy reforms, over the last few decades, have pulled out the industry from the 
shackles of import burdens and made it self-reliant. The Foreign direct investment (FDI) 
in pharma sector is allowed upto 100% for Greenfield projects (through automatic route) 
and up to 74% allowed in brownfield project (through govt.approval). The FDI reforms, to 
welcome the foreign investment with open arms, have brought far reaching ramifications 
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and have leveraged domestic markets. The sector is expected to grow at a double digit 
growth rate (15% per annum approximately) between year 2015-2020. This growth rate is 
going to outperform the rate of global pharma industry growth which is expected to grow 
at the rate of 5 per cent per annum during the same period.  
Until 1970, the recognition of product patent was not in force by law and one could only 
patent the process of making. This promoted the interest of researchers in pharmaceutical 
formulations as a result of which, India grabbed a major share in formulations and 
gradually became the largest producer, later exporter, of it. After the enactment of amended 
Patent Laws, the product patents came in as tool of securing and safeguarding the 
innovative minds. This, in fact, proved to be a boon to pharma industry. It is reflected from 
the fact that 20 brands of Indian companies are still prevailing in market for more than 10 
years from now.  
The resurgence of the Indian Pharmaceutical industry is looming large. The contribution of 
the pharma sector in country’s GDP is immense. Being the third largest (in terms of 
volume) and 13th largest (in terms of value) in the World, the industry continues to be the 
leader of generic exports worldwide. The advantage of cost, low cost of labor, cost of 
inventory is much lower in the country. The multinational companies, investing in research 
and development in India, save up to 40% to 50% of their expenses 
(source:business.mapsofindia.com). It is analyzed that cost of hiring a research chemist in 
the US is five times higher than that of India and cost of conducting clinical trials in India 
is one-tenth the cost in US.  
India presently enjoys position in global pharma market. The country has large pool of 
scientists, chemists, engineers and lab technicians who have the potential to drive the 
industry to reach new heights. It is significant to mention that more than 80 percent of the 
drugs to fight AIDS are supplied by Indian pharma companies to the World. Six companies 
of India have the UN-backed Patent pool, enabling them to supply medicines to 112 
countries of the World.  
Government of India has long recognized the strategic importance of pharmaceutical sector 
of India. India’s policies have shown immense excellence in uplifting the industry to 
transform it into a global leader for manufacturing pharmaceutical and innovations in 
medical research. A strong correlation exists between the government’s initiative of ‘Make 
in India’ and domestic pharmaceutical market. Another move of government by enacting 
GST has proved a boon to the industry by safeguarding it from multiple states tax. The 
industry is reducing its dependence upon other states now and thus strengthening its supply 
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chain. Department of pharmaceuticals of central government, in its report ‘Pharma Vision 
2020’, aims to make India a major hub of new drug and development by the year 2020 
The disclosure framework in India is governed by the principal act Indian Companies Act 
1956 (Now 2013). The act lays down the provisions and regulations of disclosures in 
financial statements. It focuses on maintenance of books and presentation of annual reports. 
The act also lays mechanisms for issuing of standards. Despite the detailed requirements 
of maintenance of books, the thrust of companies act is on ‘True and Fair view’ of company 
accounts. Another body that has a major role in influencing the disclosure framework is 
Securities and Exchange Board of India (SEBI) which governs the disclosure requirements 
of companies listed on stock exchanges. The reporting requirements imposed by SEBI 
through its guidelines are in addition to those laid by the Companies Act which is to be 
followed by the companies listed on Stock Exchange. Together, the requirements of SEBI 
and Companies Act provide a legal framework for corporate reporting in India. 
Reinforcement to the regulations of these statutory bodies, are the regulating provisions of 
Institute of Chartered Accountants of India (ICAI) which formulates Accounting 
Standards. The ICAI derives its power from the Chartered Accountants Act, 1949 
(Banerjee, 2002). The ICAI established the Accounting Standards Board (ASB) on April 
21, 1977 in order to harmonize diverse accounting policies and practices of India. The main 
task of the ASB is to formulate accounting standards, so that the council of the ICAI can 
make these standards mandatory. The ASB considers the laws, customs and business 
environment of India while formulating its standard. ICAI plays pivotal role in the 
improvement of disclosure practices of Indian companies. Accounting Standards are 
pronounced by the ICAI that applies to 'general purpose financial statements.' 
Beyond these mandatory limits of disclosure requirements, there exists a set of non 
mandatory disclosures which are completely discretionary on the part of companies to what 
extent the companies want to disclose beyond what is mandatorily required. Worth 
mentioning here that the discretionary disclosures are highlighted in a separate report called 
as Corporate Governance Report.  
1.2. Regulatory Framework of governing Corporate Disclosures in India 
1.2.1 Almost every firm in India takes a legal form as a limited liability company. Financial 
reporting of limited liability companies is mainly regulated by Companies Act 2013 (The 
then Companies Act 1956). The provisions of Act relating to Accounting and Audit are 
built around the concept of ‘True and Fair’ disclosure which characterizes the reporting in 
the UK, among other countries.  The act provides the financial statements in its schedules 
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and also lays down the penalty to be imposed both on the company and its managers 
responsible, for the non compliance with the provisions of the Act.  
1.2.2 Corporate Disclosures for the listed limited liability companies are also governed by 
the listing agreement with the stock exchange provided by the regulatory body Securities 
and Exchange Board of India.  
Clause 32 of the listing agreement with any stock exchange in India, requires a listed 
company to publish cash flow statements 
Clause 41 of the listing agreement with any stock exchange in India, a listed company is 
required to publish unaudited half yearly results.  
Clause 43 of the listing agreement with the stock exchange, companies are required to 
publish a comparison of projected Gross profit, Net Profit and Earnings per share as shown 
in the offer document in a public offer of shares with the actual performance, in the report 
of the directors in the Annual Report.  
The Non-Compliance with the provisions of the listing agreement results in delisting of the 
company’s securities from the trading on the exchange.  
1.2.3 The third element of the regulatory framework that governs disclosures in India is the 
standards and guidance Notes issued by Accounting Standard Board (ASB) of the Institute 
of Chartered Accountants of India (ICAI). Currently there are 32 Accounting standards 
which have been issued by ASB out of which 29 are mandatory and 3 are recommendatory. 
The noncompliance of the requirements of these standards will attract a qualification in the 
Auditor’s report. In addition to the standards, ICAI also issues guidance notes and 
statements. Guidance Notes are persuasive in character. They are issued as a precursor to 
an Accounting standard.  
The first and foremost Standard i.e.AS-1 is the harbinger of the Disclosure trends. AS-1 
talks about Disclosure of Accounting policies which make it mandatory for the firms to 
disclose the fundamental accounting assumptions, Nature of Accounting Policies and 
consideration in selecting policies.  
The disclosure requirements specified in the Accounting standards are in addition to and 
not in substitution of the disclosure requirements under Companies Act, 2013.  
The corporate Reporting Regulations aim at providing investors with the minimum amount 
of information to facilitate the investment decision making (Griffin & William, 1960 ) but 
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voluntary information is aimed at providing a clear view to stakeholders about the business’ 
long term sustainability (Healey and Palepu, 2001). However, argued that, voluntary 
disclosure will still remain a matter of biased information selected by managers (Core, 
2001).  
1.3 Incentives of Voluntary Disclosures 
As discussed above in the agency theory, the asymmetric may potentially bring out a 
breakdown in the functioning of the stock market; voluntary disclosures play a significant 
role to solve those information gaps. There are many factors affecting manager’s 
disclosures decisions. The most important factor that makes managers decide for voluntary 
disclosure is due to its benefits on diminishing the cost of capital. According to Capital 
Market transaction Hypothesis, it is not easy for existing shareholders to make public 
equity when a firm has high information asymmetry level. Thus, managers have incentives 
to disclose voluntarily in order to minimize the information asymmetry, and as a result, 
they can lower the firm’s cost of external borrowing when they enter into capital market 
transactions.  
However, firm may reduce voluntary disclosure due to proprietary cost associated. The 
studies of Verrechchia (1983) and Gigler (1994) show that voluntary disclosures can 
damage a firm’s competitive position when there does competition exist, and firms are 
facing a threat of entry. Higher disclosure will allow an easy entry of the competitor to the 
industry whereas low level of disclosure will keep it protected.  
Another factor which works as an incentive for voluntary disclosure is the litigation cost. 
It has two side impacts. First, firm may choose to disclose more in order to avoid litigation 
cost (Skinner 1994). There is always a trend in the stock market that investors keep a watch 
on the news whether there are delays in announcement of any unfavorable news and if there 
is any, it is evidence that firms have not disclosed voluntarily earlier in a timely manner. 
They may face serious litigations due to this. So, to avoid the threat of litigation, the firm 
may choose to disclose more information of poor performance. On the other hand, litigation 
can also reduce firm’s motivation to disclose because it may increase litigation risk. The 
penalty imposed by the legal system may be much worse as the market players forecast the 
information in good faith. Healy and Palepu (2001) suggest that firm with high level of 
positive information on future earnings are followed by high level risk of litigation. Thus, 
litigation may de-motivate firms to disclose forward looking information.  
 
Multidisciplinary Journal for Education,                                              https://doi.org/10.4995/muse.2019.11531 
Social and Technological Sciences                                                                                         ISSN: 2341-2593 
 
 
 
 
                               Khanna and Singh-Chahal (2019) 
http://polipapers.upv.es/index.php/MUSE/   Mult. J. Edu. Soc & Tec. Sci.  Vol. 6 Nº 2 (2019):   147-174 |  154 
 
Thus, Overall solution to reduce agency cost and information asymmetry is to make full 
disclosure of specific firm characteristics. In fact, it is to say that higher level of disclosure 
will have an impact on agents who indulge in withholding private information and hence 
increase transparency in the stock market.  
 
Literature Review 
In Indian Context, SEBI has laid down statutory provisions for listed companies to ensure 
compliance of transparent disclosure practices. Irrespective of sector, each company has to 
comply with those provisions. India at this time is an attractive destination of foreign 
investment. The investment environment in India has undergone a tremendous change. In 
the process of such change, knowledge of the extent of compliance is indispensable for 
domestic as well as foreign investors. Indian Pharmaceutical sector, which is 3rd largest 
growing sector in the world, under the aegis of Companies Act, 2013, ICAI pronouncement 
and SEBI regulations, is not left behind in the disclosure context. Literature has taken a 
thrust upon discussing the disclosure practices in the pharmaceutical industry in India. 
These studies have covered different aspects of disclosures, be it mandatory or voluntary. 
Kamath.G (2008) talks about the disclosure of intellectual capital in reports of 
pharmaceutical companies of India while Rajashekhar (2018) discussed corporate 
governance disclosure practices. Dasgupta.M (2003) associates company characteristics of 
Indian pharmaceutical industry with its financial performance whereas Sachdeva et al. 
(2015) does an inter-sector comparison of the disclosure practices of Indian listed 
companies including pharmaceutical sector. Sharma’s (2016) brings the discussion about 
the practices of disclosure of valuation of intangible assets prevailing in Indian 
pharmaceutical industry. Sinha et al. (2012) investigate whether the corporate disclosure 
practices of Indian pharmaceutical companies approach to harmonize with IFRS. In fact, 
after the enactment of Companies (Amendment) Act, 2013, pharmaceutical sector has even 
witnessed research on Corporate Social responsibility disclosures in the financial reports.  
The disclosure framework in Pharmaceutical sector has taken a shape after year 2011 
(Mehta & Chandani; 2015). The study of Mehta and Chandani (2015) takes top five Pharma 
companies listed on BSE for the year 2009-10 to 2014-15 and establishes relation between 
their CSR disclosures and financial performance. They assert that disclosure of CSR and 
its importance on company’s strategy has significantly improved 2011 onwards. 
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Sachdeva, Batra & Walia (2015) investigated growth in corporate disclosure practices in 
selected Indian companies listed on BSE during the year 2005-2012 from Pharmaceutical, 
FMCG, Automobile, Financial, telecom and IT Sector. The study shows that among all 
sectors, pharmaceutical sector shows the least (7%) growth in disclosure scores over the 
seven years as compared to FMCG sector where average increase is 26% since 2005.  
Halder & Mishra (2017) studied the factors affecting timeliness of information in Indian 
Pharmaceutical sector on a sample of top 50 pharma companies listed on BSE. The authors 
studied the lag in number of days that companies take to disclose during the year 2010-11 
to 2012-13. They found that there is an average maximum lag of 211 days in reporting 
information in annual reports. They asserted that Age of the company, Foreign shareholding 
and Revenue from abroad have significant impact on timeliness of disclosure.  
The other investigation on disclosure of Corporate Governance Practices by Kalashree & 
Rajshekhar (2018) on 53 listed Indian Pharmaceutical companies (mid cap and large cap) 
for the year 2013-14 found that among the ten disclosure segments that authors divided for 
disclosure score, the listed companies are liberal towards disclosing information about 
remuneration, and compliance and management aspects but disclose least about subsidiary 
companies.  
While studying various aspects of mandatory and voluntary disclosure in pharmaceutical 
sector in India, most of the previous studies ignored attributes like profitability, liquidity, 
volatility, market price of shares being affected by the nature and extent of disclosures. If 
such an association between the disclosures with the other variables is brought out, 
supported by the conclusive statistical results, the disclosure environment will set itself into 
a new pace. This study aims to contribute to the uprising pharmaceutical industry by 
motivating the industry for maximum extent of disclosures. As it is rightly said that, health 
sector, by its mere honest disclosure practices, can contribute to the healthy living of the 
masses.  
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Objective of the study 
 
To ascertain the extent of voluntary information disclosures in Indian Pharmaceutical 
Companies listed on Bombay Stock Exchange (BSE) 
 
Research Methodology 
-Sample Unit: Companies listed on Bombay Stock Exchange (BSE) 
-Sample Size: Companies listed companies from BSE (large cap having capital of more 
than Rs. 10,000crores) 
-Sector under study: Pharmaceutical sector 
-Period under study: 8 years from 2010-11 to 2017-18 
 
-Basis for selection of companies under study:  
The company is listed on the Bombay stock exchange for more than three years. 
The basis for selection is their Market capitalization 
The company’s ticker symbol does not suffer a halt for more than three months on stock 
market. 
The company’s Voluntary data should coincide at least 50% of the check list set in by the 
researcher for the purpose of study. 
The data about the company should be available.  
 
There are 170 Pharma companies listed on BSE. Out of these first twenty companies are 
large cap companies having a market capitalization of more than Rs.10, 000 crore. Out of 
the total market capitalization of Rs.7, 71,998crores, the market capitalization of these 
twenty sums up to Rs.6, 54, 792crores, which represent 84.82% of total visible pharma 
market on BSE. Rest are mid cap companies having the market capitalization between 
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Rs.2crores to Rs.10,000crores and only one small cap company having a market 
capitalization of less than 2crore. Thus, taking into consideration the magnificent impact 
of big cap firms in shaping the face of pharma market, this study takes into account only 
large cap firms as sample under study.  
Hence the sample is chosen among the twenty big cap companies listed on BSE satisfying 
the criteria mentioned under ‘basis of selection of company’. The companies, whose data 
are unavailable for any year during the period under study (Financial year 2010-11 to 2017-
18), are wiped out. Filtering such companies, the final sample size is 13 companies chosen 
among those total 20 big cap companies.  
 
Measurement of Corporate Voluntary Disclosure (VDCL)  
Prior to year 1985, Many studies had calculated disclosure quality but the concrete 
explanation about calculating the extent of voluntary disclosure was formulated by Firer 
and Meth, 1986; Wallace, 1988; Meek, Roberts and Gray, 1995. Wallace et al. described 
disclosure as an abstract construct that does not possess its own inherent characteristics. 
They developed a checklist method to score the voluntary disclosure items on a 
dichotomous scale of assigning 1 if disclosure is there and 0 is no disclosure found and 
thus; calculating the total score. Chau and Gray (2002) have also used this checklist with 
some minor changes to calculate the voluntary disclosure of Hong Kong Firms.  
 Following the same checklist method, the Corporate Voluntary Disclosure as denoted by 
VDCL is arrived at, by splitting total 55 items into six categories of different items of same 
nature placed under one category. These 55 items are extracted from a list of 71 variables, 
eliminating the mandatory ones. The sub categories are 
VDCL1= General Corporate Information 
VDCL2= External Audit Committee 
VDCL3= Financial Information 
VDCL4=Forward Looking Information 
VDCL5= Employee Information, Social Responsibility and Environmental policy 
VDCL6= Board Structure Disclosure 
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Taking into consideration the mandatory disclosure framework laid under the regulations 
of SEBI, ICAI and Accounting standards, the author has come up with the disclosure items 
that are not mandatory. The author is able to identify total 55 items of different nature 
placed under six different categories. The author goes through the annual reports of each 
company for each year from 2010-11 to 2017-18 and identifies the disclosures matching 
with the list of disclosure items under study.  
 
2. Analysis and Interpretations 
 
In the present study, in  order  to  understand  the  voluntary corporate  disclosure  practices  
followed  by the  pharmaceuticals companies selected for the purpose of study a voluntary 
disclosure index has been designed based on which the calculation is done. The index 
designed for understanding the voluntary disclosure index considers the 55 statements 
related to the voluntary disclosure broadly classified into six dimensions. The response 
about the particular statement was considered to be binomial in nature having a zero  score  
for  a  non-response  item  while  one  was  assigned  to  a  positive  response  item. The 
results of companies on a disclosure index are shown as follows: 
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         Table 1: Classification of Information Items for Voluntary Disclosure 
 
Table 1 shows that all the statements related to voluntary disclosure in the annual reports 
of the pharmaceutical companies are classified into broad 6 dimensions and consist of 55 
items related to the 6 dimensions under the study period (2010-11 to 2017-18). All the 
annual reports were considered for the study and the disclosure made in the annual 
reports are considered.  
 
Table 2: Item wise Voluntary Disclosure Score 
 
Classification of Items 2018 2017 2016 2015 2014 2013 2012  2011 
 
I. General Corporate Information 
1. General information about the 
economy 
92.31 100.00 100.00 100.00 92.31 100.00 92.31 92.31 
 
2.  Corporate mission statements          
69.23 
76.92 69.23 69.23 69.23 46.15 38.46 38.46 
 
3.   Brief history of the corporation (the 
establishment and development) 
30.77 23.08 15.38 15.38 7.69 23.08 23.08 30.77 
 
4.       Description of major 
goods/products 
38.46 15.38 30.77 23.08 23.08 38.46 15.38 15.38 
 
5.      Analysis of enterprises’ market 
share 
69.23 76.92 76.92 69.23 61.54 61.54 53.85 46.15 
 
6.       Business environment 
(economics, political…) 
23.08 15.38 15.38 15.38 23.08 15.38 15.38 15.38 
 
Sl. 
No 
Classification Item Items Percentage 
1 I.  General Corporate Information 12 21.82 
2 II. External Audit Committee 7 12.73 
3 III.  Financial Information 5 9.09 
4 IV. Forward-looking Information 9 16.36 
5 V. Employee Information, Social Responsibility and 
Environmental Policy 
14 25.45 
6 VI. Board Structure Disclosure 8 14.55 
  Total 55 100.00 
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7.      Statement disclosures relating to 
competitive position in the industry 
23.08 15.38 15.38 15.38 15.38 23.08 15.38 15.38 
 
8.      Description of marketing 
networks for finished goods/products 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
9.   Information of member companies 61.54 46.15 46.15 38.46 46.15 46.15 38.46 38.46 
 
10.  Methods of quality control 23.08 15.38 38.46 23.08 15.38 23.08 15.38 23.08 
 
11.   Company’s achieved awards 61.54 69.23 76.92 61.54 53.85 61.54 46.15 30.77 
 
12.  Corporate contributions to the 
national economy 
 
30.77 30.77 30.77 46.15 23.08 7.69 7.69 7.69 
 
II. External Audit Committee 
1.  The role and function of the audit 
committee 
92.31 92.31 92.31 92.31 84.62 76.92 76.92 76.92 
 
2.      Names and qualifications of the 
members of audit committee 
76.92 76.92 76.92 76.92 69.23 76.92 76.92 76.92 
 
3.      Number of members on audit 
committee 
84.62 92.31 92.31 84.62 84.62 76.92 76.92 76.92 
 
4.      Number of committee meetings 84.62 92.31 92.31 84.62 84.62 84.62 84.62 84.62 
 
5.   Attendance at committee meetings 53.85 53.85 53.85 53.85 53.85 46.15 46.15 46.15 
 
6.      Statement of independence 92.31 92.31 92.31 84.62 84.62 84.62 84.62 84.62 
 
7.      Report on completed work 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
III. Financial Information   
1.      Summary of financial data for the 
last 3 years or over 
84.62 76.92 69.23 61.54 61.54 69.23 61.54 
 
69.23 
 
2.      Share price information 92.31 92.31 100.00 92.31 84.62 92.31 92.31 84.62 
 
3.      Retained profit 84.62 84.62 84.62 84.62 76.92 76.92 76.92 76.92 
 
4.   Bank loan, mortgage and their use 76.92 76.92 76.92 69.23 61.54 46.15 38.46 38.46 
 
5.      Advertising and publicity 
expenditure 
 
15.38 15.38 23.08 15.38 0.00 0.00 0.00 0.00 
 
IV.    Forward-looking Information                   
1.      Factors that may affect future 
performance 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
2.   New product/service development 61.54 61.54 61.54 53.85 46.15 38.46 46.15 38.46 
 
3.   Marketing plan, distribution system 
expanding plan 
15.38 30.77 15.38 23.08 0.00 7.69 0.00 0.00 
 
4.   Effect of business strategy on 
future performance 
15.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
5.  Research and development 
expenditure 
53.85 69.23 69.23 53.85 46.15 53.85 53.85 61.54 
 
6.   Projection of cash flows 7.69 7.69 7.69 0.00 0.00 0.00 0.00 0.00 
 
7.  Earnings per share forecast 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
8.  Planned capital expenditure 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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9.  Future profit forecast 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
V.  Employee Information, Social Responsibility and Environmental Policy 
1.   Total number of employees for the 
last or more years 
84.62 84.62 76.92 76.92 61.54 61.54 46.15 46.15 
 
2. Category of employees by gender 53.85 53.85 38.46 23.08 23.08 23.08 7.69 7.69 
 
3.  Amount of employee remuneration, 
remuneration policies and bonus 
69.23 61.54 69.23 61.54 46.15 38.46 23.08 30.77 
 
4.  Policy on employee training 38.46 38.46 30.77 15.38 7.69 7.69 0.00 7.69 
 
5. Expenses for employee training 0.00 0.00 0.00 7.69 7.69 7.69 0.00 0.00 
 
6.  Reasons for change in employee 
number 
7.69 0.00 0.00 0.00 0.00 0.00 7.69 7.69 
 
7.  Qualification of the accountants 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
8.  Data on workplace accidents 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.69 
 
9.  Disclosure of welfare policy 15.38 15.38 7.69 0.00 0.00 0.00 0.00 0.00 
 
10.  Recruitment policy 30.77 23.08 15.38 7.69 0.00 0.00 0.00 0.00 
 
11.  Factors of corporate culture 15.38 7.69 0.00 7.69 0.00 0.00 0.00 0.00 
 
12.  Information about safety policy 84.62 84.62 46.15 38.46 23.08 23.08 7.69 30.77 
 
13.  Cost of safety measures 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
14.  Environment protection programs 100.00 100.00 76.92 69.23 53.85 53.85 38.46 53.85 
 
VI. Board Structure Disclosure 
1. Education and professional 
qualification of directors 
61.54 53.85 53.85 53.85 53.85 61.54 61.54 61.54 
 
2.  Directors’ interests in competing 
businesses 
30.77 30.77 38.46 23.08 23.08 30.77 23.08 23.08 
 
3. Directors’shareholding in the 
company and other related interests  
84.62 84.62 76.92 76.92 46.15 38.46 46.15 46.15 
 
4.  Number of meetings per year 92.31 92.31 92.31 92.31 84.62 84.62 84.62 92.31 
 
5. Director’s analysis of the fee and 
other benefits disclosure 
76.92 69.23 69.23 69.23 61.54 61.54 53.85 53.85 
 
6.  Role and function of the 
remuneration committee 
84.62 76.92 84.62 76.92 69.23 61.54 61.54 61.54 
 
7.  Directors’ current accounts/loans to 
officers 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
8.  Directors’interests in significant 
contracts 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
 
Table 2 shows that for calculating item wise voluntary disclosure score each of the items 
were considered and the number of companies disclosing that particular item was divided 
by the total number of companies considered for the purpose of study. In this present study 
the total number of companies selected was 13, and hence, the maximum attainable score 
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is 13. The maximum score which can be achieved in a particular year for any item will be 
100 if all the companies disclose item for all the years. The results are disappointing to see 
that only cent percent score is achieved in the first item of section I i.e. General information 
of the company. In rest all of the items the disclosure score is not so satisfactory. Startling 
to see that in items like data on workplace accidents, employee trainings or director loans, 
the score is as low as zero in consecutive years, depicting that none of the company in those 
particular years have revealed any information about these items. No doubt, the good news 
is that the trend of disclosure is escalating year by year.  
 
 
Table 3: Company wise Disclosure Scores 
Company/Year 2018 2017 2016 2015 2014 2013 2012 2011 Average 
Score  
(2010-
18) 
Average 
% 
(2010-
18) 
CADILA 25 25 18 18 19 17 17 22 20.13 36.59 
BIOCON 26 27 28 27 24 25 22 22 25.13 45.68 
CIPLA 28 27 28 24 13 13 13 13 19.88 36.14 
PIRAMAL 37 31 30 25 20 17 18 17 24.38 44.32 
DREDDY 26 28 26 23 24 26 12 12 22.13 40.23 
LUPIN 27 24 24 25 24 24 22 21 23.88 43.41 
TORRENT 15 14 14 10 8 7 7 7 10.25 18.64 
PFIZER 32 30 28 26 12 16 10 14 21.00 38.18 
GLAXO 15 16 15 17 15 16 15 15 15.50 28.18 
DIVIS LAB 17 20 20 13 15 18 18 16 17.13 31.14 
AURO 32 28 30 29 28 28 25 26 28.25 51.36 
AJANTA 16 17 17 17 18 15 14 15 16.13 29.32 
SUNPHARMA 22 22 21 20 18 16 14 15 18.50 33.64 
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Table 3 is about the voluntary disclosure scores obtained by the companies from the year 
2010-11 to 2017-18 is calculated for the companies selected for the purpose of the study. 
The range of voluntary disclosure score ranges from 10.25 to 28.25 (in absolute terms) with 
the score range ranging from 18.64 % to 51.36 %. Most of the companies could not score 
high in the voluntary disclosure scores. This is a disheartening picture of the disclosure 
practices prevailing the pharmaceutical sector. The highest score obtained is 37 (out of 55) 
by Piramal. The highest score figure is not even equivalent to 8 percent of total score 
expected. Where companies like Auro, Piramal and Pfizer are among the list of companies 
showing good amount of disclosure, the companies like Torrent, Glaxo and Ajanta are 
revealing poor disclosure scores throughout eight years of study.  
 
 
 
 
Table 4: Descriptive Statistics of Voluntary Disclosure Score 
  
2018 2017 2016 2015 2014 2013 2012 2011 
Mean 24.46 23.77 23.00 21.08 18.31 18.31 15.92 16.54 
Standard 
Error 
1.97 1.54 1.61 1.60 1.58 1.63 1.42 1.40 
Median 26.00 25.00 24.00 23.00 18.00 17.00 15.00 15.00 
Mode 26.00 27.00 28.00 25.00 24.00 16.00 22.00 15.00 
Standard 
Deviation 
7.11 5.54 5.79 5.75 5.71 5.89 5.11 5.06 
Sample 
Variance 
50.60 30.69 33.50 33.08 32.56 34.73 26.08 25.60 
Kurtosis -0.93 -0.98 -1.54 -0.62 -0.56 -0.19 -0.39 0.09 
Skewness 0.05 -0.54 -0.27 -0.56 -0.05 0.09 0.15 0.17 
 
The above table 4 depicts that mean score of the companies for voluntary disclosure 
ranges from 16.54 to 24.46 starting from the year 2011 to 2018. The mean voluntary 
disclosure score exhibits a steady increasing trend over the years; however during 
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the year 2012 the mean score marginally dipped to 15.92 from 16.54 during the 
year 2011. The year 2013 and 2014 showed the same mean score of 18.31 for the 
voluntary disclosure score. The year 2015 to 2018 showed an increasing trend 
starting from 21.08 (2015) to 24.46 (2018). The median of the voluntary disclosure 
score exhibits a steady increasing trend over the years starting from 15.00 (2011) 
to 26.00 (2018). The modal value of the voluntary disclosure score exhibits 
increasing trend over the years starting from 15.00 (2011) to 26.00 (2018), with 
fluctuations during the intermediate years with the score being 22.00(2012); 
28.00(2016), thereby exhibiting fluctuations in the intermediate years. The sample 
variance of the voluntary disclosure score exhibits a steady increasing trend over 
the years starting from 25.60 (2011) to 50.60 (2018) thereby exhibiting higher 
variability in the companies reporting the Voluntary Disclosure Scores. The sample 
skewness and kurtosis of the voluntary disclosure score exhibits normality of the 
data set over the years. 
 
 
Graph 1: Year wise Mean score of Voluntary Disclosure 
 
 
16,54 15,92
18,31 18,31
21,08 23,00
23,77 24,46
2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18
Year Wise Average Voultary Corporate 
Governance Disclosure scores
MEAN SCORE
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The above graph shows mean score of the companies for voluntary disclosure ranges from 
16.54 to 24.46 starting from the year 2011 to 2018. The mean voluntary disclosure score 
exhibits a steady increasing trend over the years; however during the year 2012 the mean 
score marginally dipped to 15.92 from 16.54 during the year 2011. The year 2013 and 2014 
showed the same mean score of 18.31 for the voluntary disclosure score. The year 2015 to 
2018 showed an increasing trend starting from 21.08 (2015) to 24.46 (2018). 
 
Table 5: Top Five Companies on the basis of Voluntary Disclosure Score 
 
 
 
 
 
 
 
The table 5 reveals the overall average Voluntary Corporate Governance Disclosure Scores 
of   the top five companies for all eight years. The chart is topped by AURO with a score 
of 28.25, followed by BIOCON (25.13), PIRAMAL (24.38), LUPIN (23.88) and 
DREDDY (22.13).  
 
3. Conclusion  
In the present study, in order to understand the voluntary corporate disclosure practices 
followed by the pharmaceutical’s companies selected for the purpose of study a voluntary 
disclosure index has been designed based on which the calculation is done. The index 
designed for understanding the voluntary disclosure index considers the 55 statements 
related to the voluntary disclosure broadly classified into six dimensions. The response 
about the particular statement was considered to be binomial in nature having a zero score 
for a non-response item while one was assigned to a positive response item. The disclosure 
scores when summed up, it was found that a maximum value that a company could attain 
any year was 37 (Piramal) out of total 55 (refer table 1). That means not even a single 
company discloses at least 80% of the proposed voluntary disclosure items considered 
under study. The companies are not disclosure friendly. Though there have been strict 
regulations laid by the regulators of the company especially after the enactment of 
companies Act 2013 that focus on strict disclosures, still the companies show a reluctance 
Rank Company Average Disclosure Score 
1 AURO 28.25 
2 BIOCON 25.13 
3 PIRAMAL 24.38 
4 LUPIN 23.88 
5 DREDDY 22.13 
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in disclosing the information. No doubt there seem to be increasing trend in the extent of 
disclosures from 2010-11 to 2017-18, yet companies like Torrent pharmaceuticals are 
existing with a disclosure score as low as 17 out of 55 in a year. Overall the increasing 
trends in last 8 years can be good news if the trend continues in same direction. Thus, 
fulfilling its one objective i.e. to know that extent of disclosure, the overall score is not so 
satisfactory.  
There may be reasons inferred from the disappointing scores of the pharmaceutical sector 
which may be hidden in the theories explaining the need for voluntary disclosure. The 
Theories like signaling theory state the deliberate supply of information beyond need can 
prove to be a reason of conflict between incentives and deterrent forces. Whereas there is 
another theory based on agency problem stating that disclosure of information also 
uncovers superior information of the top management which is not supposed to be in the 
heads of shareholders just because they are not active players of the management. But this 
demand and supply in equilibrium creates information asymmetry which may lead to 
several other consequences. Literatures have been supporting the lack of information 
supply as a cause to fluctuation of stock prices and diminishing market values of the 
companies. Another aspect of information availability is linked with entering the market 
sources for money borrowing. The interested parties may not lend to the companies having 
extra disclosures, as their idea of understanding the information, which is complex to 
decode, may bring them into the dilemma of lending decisions (which should not happen 
actually). Where, as per theory of cost of capital, more disclosures lead to decrease in cost 
of capital, the theory has proven to be contradicting itself in the studies where the disclosure 
surpassed beyond a minimal core.  
 
To conclude, the present disclosure system in India fails to distinguish between the very different 
needs of the users of the financial reports. While some users may be happy to have lengthy 
disclosures that may bring a positive impact on fluctuate of stocks in the market, others may be sent 
information that is far longer and complex to understand to make use of. The set of information 
useful for most users could be sort, precise and beyond a minimal core, no doubt, it has to be 
decided by the company to reflect its own circumstances, but the role of policy makers cannot be 
isolated in converging the global disclosure standards towards Indian pharmaceutical sector 
which is the third largest income generating sector in the world.  
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Annexure   
Following are the contents under each category: - 
                      
 
I. General Corporate Information 
1.  General information about the economy 
2.  Corporate mission statements 
3.  Brief history of the corporation (the establishment and development) 
4.  Description of major goods/products 
5. Analysis of enterprises’ market share 
6. Business environment (economics, political…) 
7. Statement disclosures relating to competitive position in the industry 
8. Description of marketing networks for finished goods/products 
9.  Information of member companies 
10.  Methods of quality control 
11. Company’s achieved awards 
12. Corporate contributions to the national economy 
II. External Audit Committee 
13. The role and function of the audit committee 
14. Names and qualifications of the members of audit committee 
15. Number of members on audit committee 
16. Number of committee meetings 
17. Attendance at committee meetings 
18. Statement of independence 
19. Report on completed work 
III. Financial Information 
20. Summary of financial data for the last 3 years or over 
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21. Share price information 
22. Retained profit 
23. Bank loan, mortgage and their use 
24. Advertising and publicity expenditure 
IV. Forward-looking Information 
25. Factors that may affect future performance 
26. New product/service development 
27. Marketing plan, distribution system expanding plan 
28. Effect of business strategy on future performance 
29. Projection of research and development expenditure 
30. Project of cash flows 
31. Earnings per share forecast 
32. Planned capital expenditure 
33. Future profit forecast 
V. Employee Information, Social Responsibility and 
Environmental Policy 
34. Total amount of employees for the last year or more years 
35. Category of employees by sex 
36. Amount of employee remuneration, remuneration policies and bonus 
 
37. Policy on employee training 
38. Expenses for employee training 
39. Reasons for change in employee number 
40. Qualification of the accountants 
41. Data on workplace accidents 
42. Disclosure of welfare policy 
43. Recruitment policy 
44. Factors of corporate culture 
45. Information about safety policy 
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46. Cost of safety measures 
47. Environment protection programs 
  
VI. Board Structure Disclosure 
48. Education and professional qualification of directors 
49. Directors’ interests in competing businesses 
50.  Directors’shareholding in the company and other related interests 
(e.g. stock options) 
51. Number of meetings per year 
52. Director’s analysis of the fee and other benefits disclosure  
53. Role and function of the remuneration committee 
54. Directors’ current accounts/loans to officers 
55. Directors’ interests in significant contracts 
 
 
